Related Experiment Videos
Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical
E Rouvier1, E Gautherot, P Meyer
1Imaging and Therapeutics Department, Immunotech SA, Marseille, France.
Abstract:
The present article reviews the clinical trials that have been performed in recurrent medullary thyroid carcinoma patients with the Affinity Enhancement System. This technique uses bispecific antibodies to target radiolabelled bivalent haptens to tumour cells. Its sensitivity in the detection of known tumour sites is high (90%) and this technique also achieves good sensitivity (61%) in the detection of occult disease as revealed by abnormal thyrocalcitonin blood levels. Due to its high targeting capacity, this technique is now considered for use as a therapeutic agent in medullary thyroid carcinoma patients.
Insights
The Affinity Enhancement System shows high sensitivity in detecting recurrent medullary thyroid carcinoma, including occult disease. This bispecific antibody technique shows promise for both diagnosis and potential therapy in these patients.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceuticals
Background:
- Recurrent medullary thyroid carcinoma (MTC) presents diagnostic and therapeutic challenges.
- Current diagnostic methods may not detect all tumor sites, especially occult disease.
- The Affinity Enhancement System (AES) is an innovative technique utilizing bispecific antibodies.
Purpose of the Study:
- To review clinical trials evaluating the Affinity Enhancement System in recurrent medullary thyroid carcinoma (MTC) patients.
- To assess the diagnostic sensitivity of AES for known and occult MTC.
- To explore the potential therapeutic applications of AES in MTC.
Main Methods:
- Review of clinical trials involving the Affinity Enhancement System.
- Description of AES as a technique using bispecific antibodies to target radiolabeled bivalent haptens to tumor cells.
- Evaluation of diagnostic sensitivity for known tumor sites and occult disease indicated by thyrocalcitonin levels.
Main Results:
- High sensitivity (90%) in detecting known tumor sites in recurrent MTC patients.
- Good sensitivity (61%) in detecting occult disease, correlated with abnormal thyrocalcitonin levels.
- The technique demonstrates high tumor targeting capacity.
Conclusions:
- The Affinity Enhancement System is highly sensitive for detecting known and occult recurrent medullary thyroid carcinoma.
- Its efficacy in targeting tumor cells supports its consideration as a therapeutic agent.
- AES represents a promising advancement for managing medullary thyroid carcinoma.